Freshpet Q3 2026: Steady 10% Growth, Margin Surge, Raised Guidance

What happened

Freshpet reported Q3 2026 results with net sales growth of 10% year-over-year, consistent with the base-case range but confirming a deceleration from the 13% growth guided for 2025. Gross margin reached 45% and adjusted gross margin 50%, a meaningful step-up from the 46.2% adjusted gross margin in the first nine months of 2025, reflecting continued scale benefits and input cost relief. Management raised and narrowed full-year 2026 guidance, signaling confidence in meeting or exceeding prior targets despite intensifying competition from Blue Buffalo's fresh rollout. These results suggest that Freshpet is defending its franchise and improving profitability, but revenue growth has settled into the high-single-to-low-double-digit range rather than the hyper-growth of prior years. The key question remains whether the company can sustain share and margin gains as competitors scale.

Implication

Investors should view the Q3 2026 print as confirmation that Freshpet can grow around 10% while expanding margins, but the stock still embeds a premium multiple (~28x EV/EBITDA on trailing numbers), so near-term upside is limited unless growth reaccelerates or margins exceed 20% EBITDA. The raised guidance is positive, but management's tone on competitive intensity and fridge expansion will be critical; watch for any sign of share loss to Blue Buffalo in upcoming quarters. The 50% adjusted gross margin is impressive and suggests structural cost advantages, but sustainability depends on volume leverage and commodity prices. Until we see a clear inflection in revenue growth or a more compelling valuation, a WAIT rating remains appropriate, with a re-entry zone near $60 or on evidence of durable double-digit growth.

Thesis delta

The investment thesis shifts modestly: margin execution is ahead of plan (50% adjusted gross margin) and supports the bull case of >20% EBITDA margins, but revenue growth of 10% confirms the base-case slowdown and underscores that the stock's premium multiple still prices in low-teens growth. Therefore, the WAIT rating is maintained with conviction 3.5, as the risk-reward remains balanced until competitive impact becomes clearer.